E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Third Quarter 2022 Financial Results
November 03, 2022 16:05 ET | electroCore, Inc.
Third quarter 2022 revenue grew 33% over third quarter 2021 Company to host a conference call and webcast today, November 3, 2022 at 4:30 pm EDT ROCKAWAY, N.J. , Nov. 03, 2022 (GLOBE NEWSWIRE) --...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces Distribution Agreement with Joerns Healthcare, LLC
November 01, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Nov. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that gammaCore Sapphire™, the first and only...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce Third Quarter 2022 Financial Results on November 3
October 27, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Neurobehavioral Outcomes in a Model of Traumatic Brain Injury
October 20, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 20, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced data from an oral presentation at Neurocritical...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Provides Select Third Quarter 2022 Financial Guidance
October 14, 2022 16:01 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents
September 21, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
Electrocore Announces Date for Fiscal Year 2022 Annual Meeting and Deadlines for Stockholder Proposals
September 20, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 20, 2022 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a commercial-stage bioelectronic medicine company, today announced its plans to hold its fiscal...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Reduces Symptoms of Acute Withdrawal in Patients with Opioid Use Disorder
September 07, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) --  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Upcoming Investor Conferences
September 06, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer,...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
August 05, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore’s Chief Executive Officer, Dan...